BioVaxys is a Vancouver-listed biotech developing peptide-based cancer immunotherapies anchored on its DPX delivery platform. The lead asset, MVP-S (maveropepimut-S), is a five-peptide survivin-targeted vaccine designed to generate cytotoxic T-cell responses against the survivin antigen that's overexpressed in many solid tumors.
The Phase 1B/2 PESCO trial in recurrent epithelial ovarian cancer earned an ASCO 2026 abstract acceptance on May 1, 2026, with the meeting scheduled for May 29-June 2 in Chicago. The PESCO regimen combines MVP-S with pembrolizumab (Keytruda) and low-dose cyclophosphamide, building on validation data presented earlier in the year that showed robust immune response across the combination. MVP-S sits in the personalized cancer-vaccine pipeline alongside Greenwich's GP2/GLSI-100 (HER2 breast cancer), Evaxion's EVX-01 (melanoma neoantigen), and Mount Sinai's PGV001 personalized neoantigen program.
The broader BioVaxys pipeline includes diphencyprone immunotherapy combinations and earlier-stage neoantigen peptide work. Stories here cover trial readouts, ASCO presentations, and the broader peptide-vaccine-plus-checkpoint-inhibitor combination strategy that has emerged as the dominant template in personalized cancer immunotherapy. See #mvp-s, #peptide-vaccine, and #ovarian-cancer.
BioVaxys presented results from the investigator-initiated PESCO trial of maveropepimut-S (MVP-S) combined with pembrolizumab and low-dose cyclophosphamide in recurrent epithelial ovarian cancer. MVP-S is a DPX-based vaccine built from five survivin-derived peptides plus a T-helper peptide and an innate immune stimulant, designed to drive a cytotoxic T-cell response against survivin, an antigen highly expressed in ovarian tumors but nearly absent in normal tissue.
ASCO 2026 abstract text released at 5 PM ET Thursday, ahead of the May 29-June 2 Chicago meeting. The peptide-oncology data landed simultaneously across the previously-announced slate. Bicycle Therapeutics released Duravelo-2 Phase 2/3 interim data on zelenectide pevedotin (BT8009) plus pembrolizumab in 1L locally advanced/metastatic urothelial cancer. Avacta released AVA6000 Phase 1b data in salivary gland cancers. BriaCell released final Phase 2 Bria-IMT survival data plus biomarker analyses from the ongoing Phase 3. BioVaxys's MVP-S PESCO Phase 1B/2 ovarian cancer abstract landed. Crinetics CRN09682 SSTR2 NDC BRAVESST2 abstract emerged. Pfizer released 40+ company-sponsored, investigator-sponsored, and collaborative oncology abstracts including three late-breaking sessions. The peptide-oncology cohort is the largest single ASCO presence in recent meeting history.
ASCO 2026 abstracts will release on asco.org/abstracts beginning 5:00 PM ET on Wednesday May 21, ahead of the May 29-June 2 Chicago meeting. The peptide-oncology slate is substantial: Pfizer announced 40+ company-sponsored, investigator-sponsored, and collaborative oncology abstracts including three late-breaking sessions; Bicycle Therapeutics has an oral and four poster presentations on zelenectide pevedotin (BT8009, nectin-4 PDC) with Duravelo-2 interim data; Avacta has Phase Ia/Ib data on AVA6000 (FAP-Dox PDC) in salivary gland cancers; BioVaxys's MVP-S survivin peptide vaccine PESCO trial data; BriaCell's six Bria-IMT/Bria-OTS+ presentations on metastatic breast cancer; and Replimune's RP1 + nivolumab 3-year melanoma OS data. Crinetics CRN09682 SSTR2 NDC BRAVESST2 update expected.
BioVaxys presented additional validation data on May 1 supporting its MVP-S DPX-formulated five-peptide survivin vaccine in combination with checkpoint inhibitor pembrolizumab and low-dose cyclophosphamide in recurrent epithelial ovarian cancer. The new data extends the immune-response readout from the PESCO Phase 1B/2 program and reinforces the clinical case heading into the company's accepted ASCO 2026 abstract presentation (May 29–June 6, Chicago). MVP-S sits alongside Bicycle Therapeutics' Duravelo-2, BriaCell's Bria-IMT, Greenwich's GP2, Immutep's eftilagimod alfa, and Pfizer's 40+ oncology abstracts on the ASCO 2026 peptide-and-immuno-oncology slate.
BioVaxys announced April 27 that the abstract from the investigator-initiated PESCO trial — an open-label, non-randomized Phase 1B/2 study evaluating the company's MVP-S (maveropepimut-S) DPX-formulated peptide vaccine in combination with pembrolizumab and cyclophosphamide in recurrent epithelial ovarian cancer — has been accepted for presentation at the 2026 ASCO Annual Meeting in Chicago (May 29–June 6). MVP-S is a five-peptide survivin-targeted formulation that pairs the peptides with a T-helper sequence and an innate-immune stimulant; the program tests whether the cytotoxic T-cell response can be combined effectively with checkpoint blockade in platinum-resistant disease.